These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
MDUK and Healx announce new partnership to identify FSHD treatmentsRead more
aTyr Pharma has released results from its phase 1/2 trial testing Resolaris in young adults with early-onset facioscapulohumeral muscular dystrophy (FSHD).
We are inviting you to join ACTMuS, a new study sponsored by King’s College Hospital and funded by the National Institute of Health Research and Muscular Dystrophy UK.
Researchers from Saint Louis University, Missouri, USA, have identified a new drug that has the potential to treat facioscapulohumeral muscular dystrophy (FSHD).
Read about the latest research developments in FSHD and workshops presented at the FSH Society Connect Conference.
We are delighted to announce that we are investing approximately £1.7 million into 10 new research projects that came out of our grant rounds.
The pharmaceutical company, Acceleron, recently announced the results of its phase I clinical trial testing ACE-083 in healthy people.
Listen to Dr Teresinha Evangelista talk about what a valuable resource the UK FSHD patient registry is.
Preliminary results of a new clinical trial suggest supplements may have a small beneficial effect on the progression of FSH but further studies are required.
We are delighted to announce funding of over £1,000,000 for neuromuscular research over the next four years.
Professor Jane Hewitt at Nottingham University has recently finished a project that aimed to increase understanding of the molecular causes of facioscapulohumeral muscular dystroph